BioSpace News Archive

Drug Development

Evelo Stock Soars After Asset Tapped for Phase II/III COVID-19 Study in the U.K.

The TACTIC-E trial will investigate the safety and efficacy of experimental therapies designed to prevent and treat life-threatening complications associated with COVID-19 in hospitalized patients who are at early stages of the disease.

June 22, 2020
·
2 min read
·
Alex Keown
Business

Gilead to Test Inhaled Form of Remdesivir in COVID-19 Starting in August

In an open letter from the company’s chairman and chief executive officer, Daniel O’Day reported that the U.S. Food and Drug Administration (FDA) had given the company approval to begin clinical trials of an inhaled version of the drug.

June 22, 2020
·
4 min read
·
Mark Terry
Drug Development

Biopharma Update on the Novel Coronavirus: June 22

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.

June 22, 2020
·
3 min read
·
BioSpace Editorial Staff
Drug Development

Merck’s Experimental Pneumonia Vaccine Hits the Mark in Two Phase III Studies

Merck’s investigational pneumonia vaccine, V114, hit the mark in two Phase III studies, including one involving adult HIV patients.

June 22, 2020
·
2 min read
·
Alex Keown
Business

Codiak Receives $72.5 Million Up Front from Sarepta in Neuromuscular Disease Research Pact

Sarepta Therapeutics entered into a research alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases.

June 22, 2020
·
3 min read
·
Mark Terry
Drug Development

9 Meters Beats Corporate Competitors to Phase III Celiac Trials

With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.

June 22, 2020
·
4 min read
·
Gail Dutton
Business

MMR Vaccine Could Invigorate the Innate Immune System to Fight COVID-19

As companies scramble to develop a vaccine against the SARS-CoV-2 virus, a team of husband and wife researchers have found that the measles, mumps, rubella (MMR) vaccine can reduce the symptoms of COVID-19.

June 22, 2020
·
4 min read
·
Gail Dutton
Drug Development

Ridgeback Aims Antiviral at COVID-19 in Two Phase II Studies

Ridgeback Therapeutics will launch two mid-stage programs assessing the efficacy of its antiviral candidate EIDD-2801 as a treatment for COVID-19.

June 22, 2020
·
2 min read
·
Alex Keown
Venture Capital Firm Epidarex Closes New Life Sciences Fund Worth $126 Million

It will focus on building new life sciences companies coming out of research in the UK, including spinouts from universities.

June 22, 2020
·
3 min read
·
Mark Terry
Biotech Beach

Greater cfDNA Recovery May Help Accelerate Development of Cancer Liquid Biopsy Applications

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.

June 22, 2020
·
2 min read